A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/Refractory Solid Tumors
This Study is
No Longer Enrolling
Details
Locations
Outpatient CTRC
University of Colorado Hospital
Study ID
Protocol Number: 19-1069
More information available at ClinicalTrials.gov: NCT03986606
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers